We encourage you to republish this article online and in print, it’s free under our creative commons attribution license, but please follow some simple guidelines:
  1. You have to credit our authors.
  2. You have to credit SciDev.Net — where possible include our logo with a link back to the original article.
  3. You can simply run the first few lines of the article and then add: “Read the full article on SciDev.Net” containing a link back to the original article.
  4. If you want to also take images published in this story you will need to confirm with the original source if you're licensed to use them.
  5. The easiest way to get the article on your site is to embed the code below.
For more information view our media page and republishing guidelines.

The full article is available here as HTML.

Press Ctrl-C to copy

Global collaboration is needed to combat tuberculosis (TB), says this editorial in The Lancet.

A major threat to this effort is drug resistance. Extensively drug-resistant TB has been found in 35 countries, with the World Health Organization (WHO) estimating that US$650 million will be needed this year alone for its control.

Coinfection of TB patients with HIV is another important challenge, affecting around 11 million people worldwide. Yet clinical care for these diseases is often disjointed and TB and HIV/AIDS control programmes must have a more coordinated approach, says the editorial.

There is also a need for more synchronised funding approaches. HIV/AIDS research receives ten times more funds than TB research. The biggest shortfall occurs in Africa, where the disease burden is highest for both diseases.

The editorial does stress that TB control is working in some areas. According to the WHO, 26 countries achieved their 2005 targets. TB could be eradicated by 2050, but only if all countries commit to TB control and donors fund more effective delivery services in the developing world.

Link to full article in The Lancet (requires free registration)